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Abstract
Background: Cancer has a lot of consequences on patients’ quality of life (such as cancer-related fatigue (CRF),
sleep difficulties and emotional distress) and on patients’ partners and their relationship, such as distress and
communication difficulties. These consequences are undertreated, and interventions based on hypnosis often focus
on breast cancer patients only. This paper describes the study protocol of a longitudinal randomized controlled trial
aiming to assess the efficacy of an 8-week intervention combining hypnosis and self-care to improve cancer patients’
CRF, sleep and emotional distress and to indirectly improve their partners’ distress.
Methods: A power analysis required a total sample of 88 patients. To test the efficacy of the intervention, results of the
experimental group receiving the intervention will be compared to those of the control group. Data will be collected
by questionnaires, relaxation tasks, an attentional bias task, and everyday life assessments measured at four different
times: 1.) before inclusion in the study (baseline); 2.) after the intervention; and 3.) at 4- and 12-month follow-up.
Partners’ symptoms will also be evaluated with questionnaires at the same measurement times.
Discussion: There is a growing interest in alternative approaches (such as hypnosis) in addition to standard therapies
in oncology settings. The results of this study should be useful for improving knowledge about long-term efficacy of
hypnosis-based group interventions for CRF, sleep and distress among all types of cancer patients and their partners,
and to better understand the mechanisms of emotional regulation in cancer patients through the attentional bias task.
Trial registration: ClinicalTrials.gov (NCT03144154). Retrospectively registered on the 1st of May, 2017.
Keywords: Oncology, Group intervention, Hypnosis, Fatigue, Emotional distress
Background
It is predicted that 40% of the population will be diag-
nosed with cancer at least once, which has a lot of conse-
quences for them and their relatives [1, 2]. First, a
meta-analysis showed that 46–99% of cancer patients
experience cancer-related fatigue (CRF) [3], which can be
defined as “a distressing persistent, subjective sense of
physical, emotional and/or cognitive tiredness related to
cancer or cancer treatment that is not proportional to
recent activity and interferes with usual functioning” [4].
The burden of CRF is high for patients who must endure
social, financial, and functional negative consequences
associated with this symptom [3, 5]. Second, a large pro-
portion of cancer patients suffer from emotional distress,
defined as “an unpleasant experience of an emotional, psy-
chological, social, or spiritual nature that interferes with
the ability to cope with cancer treatment” [6–10]. Emo-
tional distress negatively influences treatment adherence
[6] and results [6, 11, 12], and patient’s general quality of
life [6, 13]. Fear of cancer recurrence is also linked to
emotional distress [14–16]. One explanatory process of
this relationship could be the presence of an attentional
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bias toward threat, which can be defined as selective pro-
cessing of threatening information; in this case it is refer-
ring to cancer-related information [17–20]. Third, cancer
also affects patients’ relatives. Partners of cancer patients
often become the main caregiver for their ill spouse [21,
22] and can feel distressed [23–25] and tired [26, 27].
Changes in couple’s communication, intimacy, and shar-
ing of responsibilities has also been noted [28–30]. Pa-
tients’ emotional distress and CRF in addition to their
partners’ burden can persist for years after the end of can-
cer treatments [5, 31–33].
Despite the prevalence of patients’ emotional distress
and CRF, and the impact of cancer on relatives, these
consequences are still underdiagnosed and undertreated
by healthcare professionals [6, 7, 34]. Some studies have
shown the positive impact of psychological interventions
on patients’ emotional distress [34–36] and CRF [35–
38]. Some alternative methods such as hypnosis-based
interventions have also been tested. Hypnosis can be de-
fined as “a procedure during which a health professional
or researcher suggests that a patient or subject experi-
ence changes in sensations, perceptions, thoughts, or be-
haviour” [39]. Several studies have demonstrated the
positive impact on various sides effects of cancer treat-
ments such as CRF, sleep, and distress of hypnosis
taught alone [36, 38, 40–45], or combined with self-care
techniques [41, 46, 47]. Most of these studies focus on
breast cancer patients. However, other cancers may have
different adverse physical and psychological effects. For
example, mortality rates vary according to the localisa-
tion of the tumour [48]. Additionally, some cancers such
as prostate and gynaecological cancer directly impact
the patients’ sexuality, because they alter or remove sym-
bols of masculinity or femininity (e.g. erection, libido,
fertility…) [49–53], with high impact on couple’s intim-
acy and communication [29, 54–56]. Another example
relates to brain tumours, which can lead to cognitive
deficits, aphasia, visual field defects, motor deficits and
personality changes [57, 58]. All these adverse effects are
specific to the type of cancer and may have specific im-
pact on the psychological adaptation to the disease.
Objectives
Our primary goal is to assess the efficacy of an 8-week
group intervention combining hypnosis and self-care to
improve fatigue in all types of cancer patients, after
treatments. The secondary goals are to assess the effi-
cacy of this intervention to improve other patients’
well-being-related variables (emotional distress (anxiety
and depression), sleep, fear of cancer recurrence, psy-
chological adjustment to the disease, emotional regula-
tion skills, cognitive functioning, and physical activity).
As the intervention will address various fields such as
communication with relatives, we will also assess its im-
pact on the couple’s dynamic, and on partner’s distress.
Finally, the link between the decrease in patients’ dis-
tress and a possible attentional bias will be assessed in
order to better understand the emotional regulatory
mechanisms in cancer patients.
Methods and design
Design
Figure 1 illustrates the longitudinal randomized waiting-
list controlled trial design used in our study. Ethics
approval has been obtained from the Comité d’Ethique
Hospitalo-Facultaire Universitaire de Liège. The waiting-
list control design allows every participant to benefit
from the intervention, which will make it possible to
recruit more patients than in a no-treatment control
design. It also controls the influence of natural recovery
from cancer treatments and spontaneous improvement
or deterioration of symptoms [59]. Each intervention
Fig. 1 Design of the study
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will start when 16 patients have successfully completed
the screening and the first measurement time (T1).
Those patients will be randomized into two groups of
eight participants: the first group will receive immediate
intervention (intervention group) and; the second group
will receive it (at the latest) 4 months later (waiting-list
control group).
The randomization process will be conducted by the
principal investigator. Our clinical experience showed us
that breast cancer patients are more likely to participate
in such intervention. Despite the fact that we do not aim
to compare the efficacy of our intervention between dif-
ferent cancer diagnoses, we will ensure that cancer diag-
noses are equally allocated between the two groups
(experimental vs control) because we want the same
number of breast cancer patients in each of these
groups. The researcher will conduct two randomizations:
one for the breast cancer patients, and one for the other
cancer patients. The draw will be operated through a
specialized website (https://www.dcode.fr/tirage-au--
sort-nombre-aleatoire) in which the investigator will
introduce the codes of the participants and ask the soft-
ware to divide them into two groups (experimental and
control groups). The participants do not know the group
in which they are included (experimental vs control)
until the end of the first evaluation, when the experi-
menter tells them (T1). The first intervention group
started in April 2017, and the waiting-list control group
started in July 2017.
Eligibility
Inclusion criteria include several parameters:
1) age 18 years or older;
2) fluent in French;
3) no history of psychiatric disorders, such as
dementia, psychosis or delirium, which does not
allow participation in a group intervention or
completion of the evaluations;
4) diagnosis of non-metastatic cancer (all tumour loca-
lisations accepted); we did not include metastatic
patients in order to minimize baseline differences in
the sample, as the changing nature and complexity
of metastatic cancers could make it difficult to
compare the results with non-metastatic cases [60];
5) all active treatments completed for less than a year
(surgery, chemotherapy, and/or radiotherapy), in
order to form a group of participants who were
recently involved in diagnosis and treatments and
so increase the likelihood that the difficulties they
are dealing with will be more similar;
6) no relapse at the time of inclusion;
7) difficulties as established by responses of at least 4
out of 10 on 1 of the 6 chosen items of the
Edmonton Symptom Evaluation Scale [61]; these
include physical fatigue, moral fatigue (we decided
to split the original item “fatigue (lack of energy)”
into two different items, in order to investigate both
physical and psychological sides of fatigue),
depression, anxiety, fear of recurrence, or
ruminations. This cut-off score was chosen to avoid
floor effects [59].
Recruitment
Participants will be recruited over a 2-year period at the
University Hospital of Liège (Belgium). Potentially eli-
gible participants are identified in several ways. First,
healthcare professionals working with cancer patients
(mostly oncologists, radiotherapists, psychologists, and
nurses) are informed of the study and asked to talk
about it to their non-metastatic patients who have fin-
ished their treatment. Interested patients should directly
report to the experimenter or are advised to contact us
by phone. Second, flyers and posters are displayed in dif-
ferent strategic areas in the hospital (mostly in oncology,
radiotherapy, and algology services’ waiting rooms),
which allow other health professionals and patients to
be informed about the study and to contact us to partici-
pate or to talk about the study. Finally, in collaboration
with the social nurse, all eligible patients are directly
met after their last radiotherapy session, and are offered
to participate in the study. Review of the trial process
and difficulties encountered are discussed once a month
between the researchers. This permitted to improve our
recruitment strategies.
The recruitment started in December 2016 and is on-
going. Sample size has been determined by a power ana-
lysis in order to detect a difference in the evolution of data
between the two groups. The sample size calculation was
based on an independent samples t-test for a difference in
mean scores. Alpha was set at 0.05, power at 90% and the
standardized effect size at 0.7. The Cohen’s d of 0.7 is con-
sidered to be a medium to high effect size. Psycho-oncol-
ogy studies which aim to assess the effect of an
intervention on the patients’ quality of life often use effect
sizes between 0.6 and 0.8 to calculate the sample size [62,
63]. According to this analysis, 44 patients are required in
each group for a total of 88 patients.
Procedures
A written consent is obtained by the experimenter from
each participant at the beginning of the study.
Screening (T0)
During the first telephone contact with the interested par-
ticipants, they are informed of the protocol and study de-
sign. All participants are informed about study procedures
and in particular, that they will receive the intervention
Grégoire et al. BMC Cancer         (2018) 18:1113 Page 3 of 10
immediately or after 4 months, according to the group
they will be assigned to. If interested, the researcher
ensures that participants meet all the inclusion criteria. If
eligible, two appointments for the first evaluation (T1) are
scheduled.
Measurement points (T1, T2 and T3)
Each of these three measurement points is completed by
every participant and is divided into two sessions, sepa-
rated by a 9-day interval (see Fig. 1). We decided to div-
ide into two sessions in order to minimize the burden
encountered by the participants. The first session (about
2 h 30min) is dedicated to the completion of several
questionnaires and the realization of two relaxation ex-
ercises (see Table 1). During the whole session, a cardiac
holter monitor is placed on participants to measure their
heart rate. The second session (about 1 h 15min) is ded-
icated to a computerized attentional task and to the
completion of some questionnaires and open questions
(see Table 1). During the 9-day interval, participants
wear an actigraph (Garmin Vivoactive® HR) which mea-
sures heart rate, physical activity, and sleep. As partici-
pants do not have to do anything else with the actigraph
than to recharge it, it is not considered to be compli-
cated. The experimenter also installs an application on
their smartphone (RealLife Exp, pack LifeData V5),
which asks them about their emotions six times a day.
In Belgium, 64% of 45–54-year-old use a smartphone,
while 53% of people aged of 55 or more use one [64].
We conclude, therefore that it is likely that most of our
participants are able to use a smartphone. However, a
smartphone is lent to those who don’t have one and ex-
planations are given if necessary. The experimenter also
remains available by phone or email between the ses-
sions to answer any question. Some questionnaires for
partners are also given to the participants who have one
with instructions to ask their spouse to complete them
in order to collect data about partners’ well-being.
Consent forms for partners are attached to these
questionnaires. At the end of the first measurement
point, participants are informed of the result of the
randomization and their allocation in either the inter-
vention group or the waiting-list control group.
One-year follow-up (T4)
One year after having participated in the intervention,
each patient is contacted by the researcher to schedule a
final group session with the therapist in order to evalu-
ate the long-term benefits of the intervention. They dis-
cuss the application of learned skills in their daily life,
perform one hypnosis exercise, and participants also
have to complete some questionnaires (see Table 1). We
expect the follow-up participation rate to be high, as
most patient really appreciate the group session.
At each measurement point, the risk of missing responses is
very low, as patients complete the scales in the presence of the
investigator, who check every questionnaire after completion.
All data are anonymized. A code is attributed to each partici-
pant and used during the whole study. Only the researchers
involved in this study have access to the final datasets.
Table 1 Patients’ measures used in the study
T0
Screening









- VAS (psychological state)


















- Self-relaxation task +
Questionnaire about
relaxation strategies
- Guided relaxation task +
Questionnaire about
relaxation habits
Between session 1 and





- Actigraph to measure sleep,
activity and heart rate.
Session 2
Questionnaires
- VAS (motivation and
implication)











Abbreviations: VAS Visual Analogue Scales, ESAS Edmonton Symptom
Assessment Scale, HADS Hospital Anxiety and Depression Scale, PSWQ Penn
State Worry Questionnaire, FCRI Fear of Cancer Recurrence Inventory, MAC
Mental Adjustment to Cancer Scale, WBSI White Bear Suppression Inventory,
MFI-20 Multidimensional Fatigue Inventory, CERQ Cognitive Emotion
Regulation Questionnaire, ICQ Impact of Cancer Questionnaire, ISI Insomnia
Severity Index, FACT-Cog Functional Assessment of Cancer Therapy – Cognitive
Function, FFMQ Five Facets Mindfulness Questionnaire, MCQ-30 Metacognition
Questionnaire, PTGI Post-Traumatic Growth Inventory, CICS Couples’ Illness
Communication Scale, DCI, Dyadic Coping Inventory
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Intervention
The intervention combining self-care and hypnosis in-
cludes eight weekly 2-h sessions in group of eight partic-
ipants. This has been developed and is being led by one
of the authors (MEF), who is an anaesthetist and an
international expert in hypnosis. She introduced the use
of hypnosis as an alternative for anaesthesia in surgery
in our hospital in 1991, and has been the head of the
continuing and palliative care unit since 2010, where she’s
supported cancer patients for decades, basing her ap-
proach on self-care tasks [65]. She has led self-hypnosis
and self-care groups since 2008 for chronic pain patients,
and since 2013 for cancer patients.
The self-care approach is used to foster decision-mak-
ing through the use of different tasks focused on
well-being rather than on the disease itself. Participants
have to complete these assigned tasks at home between
sessions and keep a work-related diary to report how
they managed it in their daily life. Examples of assign-
ments are: adjusting self-expectation, reinforcing sense
of self-esteem, revising self-narrative, adaptation of social
roles, finding one’s own boundaries and personal needs,
assertiveness, identifying situations and feeling of power-
lessness, accepting that not everything is controllable,
differentiating self from illness, managing ruminations,
etc. These tasks illustrated with metaphors and humoris-
tic anecdotes are given to patients in a practical and di-
dactic way. This approach is based on self-management
and patient empowerment approaches, which aim to
strengthen self-esteem, assertion and self-confidence. Pa-
tients are encouraged to observe their thoughts and acts,
and the different tasks proposed during and between
sessions help them to detect and react to difficult situa-
tions. In this way, patients learn to adopt concrete
changes aiming to respect themselves and others. They
also learn to focus attention to positive things, life events
that are going well, and to be grateful for “being alive”.
An interactive and positive virtuous circle is constructed
with patients all along sessions [47, 66]. Patients are
asked to be actively involved in the process since the
aim is to introduce change in their daily routines. In
many ways, our strategies are similar with those devel-
oped in the cognitive-behavioural therapy (CBT) which
is a “time-sensitive, structured, present-oriented psycho-
therapy directed toward solving current problems and
teaching clients skills to modify dysfunctional thinking
and behaviour” and which is “based on the cognitive
model: the way that individuals perceive a situation is
more closely connected to their reaction than the
situation itself.” [67]. However, our intervention does
not use CBT techniques such as cognitive restructura-
tion or functional analysis by analysing a specific situ-
ation to understand its origin, but more generally to
apprehend the future.
Concerning hypnosis, a large part of the first session is
devoted to answering the participants’ questions and
giving information about hypnosis. At the end of each
session, a 15-min hypnosis exercise is conducted under
the therapist’s supervision. Participants receive a CD for
each exercise to encourage at-home practice, which is
essential to take full advantage of hypnosis without the
help of a therapist. It is attended that the practice of
self-hypnosis will influence cognition and emotional
regulation and therefore facilitate the completion of the
assigned tasks. In this way, self-hypnosis is complemen-
tary to self-care tasks.
During the whole study duration, every participant in
each group benefits from usual care, including medical
care, oncological revalidation and individual psycho-
logical help if necessary. Although no adverse event has
been reported in our previous studies [46, 47, 68], it
could be possible that a patient feels uncomfortable dur-
ing the group discussions or hypnosis exercises. In this
case, they always have the possibility to stop the session
or their participation in the study. The therapist or the
experimenter can also propose a meeting to discuss their
difficulties and, if necessary suggest a meeting with a
psychologist or another health professional. Any reason
for drop-out will be consigned.
Assessments
Table 1 displays the different parameters used at each
measurement time. They are detailed below.
Questionnaires
For patients All questionnaires are detailed in
Additional file 1: Appendix 1.
General information: Sociodemographic and medical
data such as gender, age, language, professional activity,
family members, personal history of cancer and treat-
ment are collected. Some questions are also asked about
life habits (physical activity, medication, alcohol and
drug use, for example), and important life events.
Physical and psychological functioning is assessed
through the use of several questionnaires: Visual
Analogue Scales (VAS), the Edmonton Symptom Assess-
ment Scale (ESAS) [61], the Hospital Anxiety and De-
pression Scale (HADS) [69], the Penn State Worry
Questionnaire (PSQW) [70], the Fear of Cancer Recur-
rence Inventory (FCRI) [71], the Mental Adjustment to
Cancer Scale (MAC) [72], the White Bear Suppression
Inventory (WBSI) [73], the Multidimensional Fatigue In-
ventory (MFI-20) [74], the Cognitive Emotion Regula-
tion Questionnaire (CERQ) [75], the Impact of Cancer
Questionnaire (ICQ) [76], the Insomnia Severity Index
(ISI) [77], the Five Facets Mindfulness Questionnaire
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(FFMQ) [78], the Post-traumatic Growth Inventory
(PTGI) [79] and the Rosenberg’s self-esteem scale [80].
Cognitive functioning is assessed with the Functional
Assessment of Cancer Therapy – Cognitive Function
(FACT-Cog v.3) [81] and the Metacognition Question-
naire (MCQ-30) [82].
Conjugal functioning is assessed using two question-
naires: the Couples’ Illness Communication Scale (CICS)
[83] and the Dyadic Coping Inventory (DCI) [84].
Relaxation strategies is investigated using two ques-
tionnaires about relaxation strategies used during the
first exercise and about relaxation habits. These were
created for the study.
Finally, the questionnaire about the intervention is
focused on expected and perceived benefits from the
intervention both for oneself and the partner (open
questions).
For partners Partners complete five questionnaires:
– Sociodemographic and medical information
– Hospital Anxiety and Depression Scale [69]
– Couples’ Illness Communication Scale (CICS) [83]
– Dyadic Coping Inventory (DCI) [84]
– Expected and perceived benefits from the
intervention, for oneself and for the patient.
Tasks
Three tasks are suggested to the participants:
– Two relaxation exercises: Anxiety regulation is
measured during two relaxation exercises. Before
each exercise, anxiety is triggered by the completion
of the MAC (before exercise 1) and the ICQ (before
exercise 2) questionnaires. During the first exercise,
participants have to use their own strategies to relax
by themselves for about 13 mins, and during the
second, they are guided by an audio recording for
approximately the same time. Heart rate (beats per
minute) is measured during the exercises by the
Lifecard CF holter monitor as an indicator of
anxiety regulation [85]. Heart rate variability has
been shown to be correlated with emotion
regulation [86] and influenced by emotional distress
(depression and anxiety) [87, 88].
– An attentional task: A computerized task is used to
assess the attentional bias toward threat. This
computerized task, designed by the Université Libre
de Bruxelles (ULB, Belgium), aims to evaluate the
intensity of the attentional bias toward emotional
information. Several pairs of words (each word
being positive, negative, or neutral; and related or
not related to cancer) are presented to the
participants, followed by a point, located at the same
place as one of the two words. The participants have
to click on the up or down button of the keyboard
depending of the location of the point. An increased
response time for points following cancer-related
words could suggest the presence of an attentional
bias towards threat. Response time and accuracy will
be measured in order to calculate different atten-
tional bias indexes [18], which will evaluate the se-
verity of the bias before and after the intervention.
Ecological momentary assessments
Different ecological momentary assessments will be made
between the two evaluation sessions with the experimenter.
– Emotional regulation: At each measurement point,
participants have to use an application on a
smartphone for 9 days. This application was
designed by ULB and aims to evaluate the emotional
state of the participant at six different times of the
day (intensity and perceived controllability of
emotions, and energy level).
– Activity and sleep measurements: At each
measurement point, participants wear an actigraph
(Garmin Vivoactive® HR), which measures their
physical activity (number of steps per day) and their
sleep (number of hours of deep and light sleep per
night and waking time after initial sleep onset) for 9
days. Wrist actigraphs provide an accurate 24-h
sleep assessment and activity patterns in a natural
environment [89, 90] and have been used in several
studies with cancer patients [90–92].
Data coding and storage
Most questionnaires are completed electronically (on a
computer) by the participants. Data encoding will be as-
sured by an independent team, in an automatic comput-
erized way. They have no contact with the patients. Final
databases, and manually coded data (data from the
actigraphs, partners’ questionnaires) are stored on the
experimenter’s computer, protected by a password.
Statistical analyses
Baseline (T1) demographic, medical, and psychological
data will be compared between groups to test for initial
groups equivalency using inferential statistics, including
analyses of variance (ANOVA) and chi-square tests.
Group-by time changes, and pre- and post-assessment
comparison of each variable within each group will be
assessed using repeated measures MANOVA, on the par-
ticipant who completed all the needed assessments times.
The link between a decrease in distress and attentional
bias will be assessed by correlations. Correlations will also
be used to assess the links between the data from the pa-
tients and their partners, and we will measure the
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evolution of the partners using repeated measures MAN-
OVA. All tests will be two-tailed, and the alpha will be set
at 0.05. Statistical analyses will be performed after T3 and
after T4.
All participants will be informed by e-mail about the
final results of the study. Scientific publications will also
be planned.
Discussion
Few studies in oncology focus on CRF in cancer patients
and interventions investigated in such studies are often
traditional ones [37, 38]. Hypnosis-based interventions
are starting to be evaluated as a way to improve quality
of life as well [36, 40, 42]. However, long-term data
about the effects of such interventions are missing, most
studies included only breast cancer patients, and very
few included partners in their assessments. Finally, very
few studies have investigated the explanatory mecha-
nisms of emotion regulation in cancer patients.
Thereby, our study would make a great contribution
as it focuses on CRF, sleep, and emotional distress [6, 7,
34], and provide a long-term assessment of intervention
effects. The randomised controlled design is also a
strength of our study. Plus, it includes all types of cancer
(except for metastatic ones) and all type of treatment,
and evaluates the effects of the intervention on patients’
partners and on couple functioning. Finally, our study
investigates the link between the attentional bias toward
threat and emotion regulation, contributing to better
understand the mechanisms of emotion regulation in
cancer patients.
We made several hypotheses on the impact of the
intervention: 1) fatigue and emotional distress will de-
crease in response to the intervention, and sleep and
emotional regulation will improve; 2) dyadic coping and
communication in the couple will improve, and partner’s
distress will decrease; and 3) there will be a positive as-
sociation between the decrease of patients’ distress and
the decrease in the attentional bias.
These assumptions follow from the three major com-
ponents of hypnosis that could influence cognition and
emotional regulation: absorption, which is the involve-
ment in a perceptual, imaginative or ideational experi-
ence; dissociation, which is the mental separation of
different components of experience that would usually
be processed as a whole; and suggestibility, which is the
responsiveness to social clues, enhancing the propensity
to comply with hypnotic instructions and suspending
critical judgment [93]. Those hypnotic suggestions also
seem to facilitate mind-body connection and lead to
physical, emotional and behavioral changes [94].
There are some limitations of our study. The number
and length of assessments completed by the participants
could lead to some dropouts. It is possible that only
motivated and compliant patients will complete all the
assessments, which would bias the results of the study.
However, it is important to point out that the partici-
pants have to complete assessments with at least a
3-month interval between them, which reduces the pos-
sible burden experienced by the participants. Another
limitation is the fact that our intervention has only been
proposed for non-metastatic patients in order to
minimize the baseline differences of the sample.
In conclusion, our study will provide the initial insight
into the short and long-term effects of an intervention
combining hypnosis and self-care on the quality of life
of all types of cancer patients in remission, on partners’
well-being, on the quality of the conjugal relationship,
and on links between emotional regulation, distress, and
attentional bias.
Additional file
Additional file 1: Appendix 1. Questionnaires used in the study.
Description of the questionnaires used in the study. (DOCX 25 kb)
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